Search - tctmd.com

Displaying 21 - 34 of 34

Sort: Relevancy | Date

Presentation TCT 2019

Patient Selection for MitraClip in Heart Failure With FMR: What Are the “COAPT Criteria” and Where (if Anywhere) Might They Be Stretched?

Presenter: Milton Packer

September 26, 2019

News Daily News

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

L.A. McKeown

August 21, 2019

Presentation TVT 2019

Proportional vs. Disproportional Mitral Regurgitation — The New Paradigm

Presenter: Milton Packer

June 14, 2019

News Daily News

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Shelley Wood

May 09, 2019

News Features

Mercury Rising: As Doctors’ Groups Face Off Over BP Guidelines, Will Patients Fall Through the Cracks?

L.A. McKeown

February 26, 2018

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Shelley Wood

November 13, 2016

News Conference News AHA 2016

Early Vasodilator Therapy Not the Answer for Improving Long-term Outcomes After Acute Decompensated Heart Failure

Todd Neale

November 13, 2016

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Industry News

Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure

December 10, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Industry News

Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure

May 22, 2015

Evaluating the Heart Failure Patient with MR: Integrating Train Data Into Clinical Practice

CME

Advertisement

Patient Selection for MitraClip in Heart Failure With FMR: What Are the “COAPT Criteria” and Where (if Anywhere) Might They Be Stretched?

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

Proportional vs. Disproportional Mitral Regurgitation — The New Paradigm

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Mercury Rising: As Doctors’ Groups Face Off Over BP Guidelines, Will Patients Fall Through the Cracks?

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Early Vasodilator Therapy Not the Answer for Improving Long-term Outcomes After Acute Decompensated Heart Failure

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure

Evaluating the Heart Failure Patient with MR: Integrating Data Into Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content